Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

847 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.
Komatsu H, Matsumoto K, Morita M, Nagasawa T, Nishio H, Suzuki J, Nishio S, Kobara H, Yunokawa M, Ariyoshi K, Hirayama T, Tokunaga H, Ukita M, Yoriki K, Mori-Uchino M, Furusawa A, Togami S, Nakamura H, Ishikawa M, Satoh T. Komatsu H, et al. Among authors: nishio h, nishio s. Cancer Med. 2024 Mar;13(5):e6968. doi: 10.1002/cam4.6968. Cancer Med. 2024. PMID: 38491829 Free PMC article.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Among authors: nishio s. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Maeda T, Najima Y, Kamiyama Y, Nakao S, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miumra Y, Endo M, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Yano S. Maeda T, et al. Among authors: nishio h. Int J Clin Oncol. 2024 May;29(5):535-544. doi: 10.1007/s10147-023-02465-0. Epub 2024 Mar 18. Int J Clin Oncol. 2024. PMID: 38494578 Free PMC article.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Tsuchihashi K, Ito M, Okumura Y, Nio K, Ozaki Y, Nishio H, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Baba E. Tsuchihashi K, et al. Int J Clin Oncol. 2024 May 2. doi: 10.1007/s10147-024-02541-z. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38696053
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Najima Y, Maeda T, Kamiyama Y, Nakao S, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Miumra Y, Endo M, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Yano S. Najima Y, et al. Int J Clin Oncol. 2024 May 17. doi: 10.1007/s10147-023-02461-4. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38755516
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Ozaki Y, Yokoe T, Yoshinami T, Nozawa K, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T. Ozaki Y, et al. Int J Clin Oncol. 2024 May;29(5):551-558. doi: 10.1007/s10147-024-02499-y. Epub 2024 Mar 25. Int J Clin Oncol. 2024. PMID: 38526621
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Kimura S, Shigeta K, Tamura S, Uchino K, Kimura T, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Miura Y. Kimura S, et al. Int J Clin Oncol. 2024 May;29(5):559-563. doi: 10.1007/s10147-024-02501-7. Epub 2024 Mar 28. Int J Clin Oncol. 2024. PMID: 38538963
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Ito M, Okumura Y, Nio K, Baba E, Ozaki Y, Nishio H, Ichihara E, Miura Y, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ochi N, Kubo T, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Tsuchihashi K. Ito M, et al. Int J Clin Oncol. 2024 Apr 5. doi: 10.1007/s10147-024-02502-6. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38578596
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Uchino K, Tamura S, Kimura S, Shigeta K, Kimura T, Ozaki Y, Nishio H, Tsuchihashi K, Ichihara E, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Ochi N, Kubo T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Miura Y. Uchino K, et al. Int J Clin Oncol. 2024 May;29(5):545-550. doi: 10.1007/s10147-024-02491-6. Epub 2024 Mar 22. Int J Clin Oncol. 2024. PMID: 38517658
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Ichihara E, Ochi N, Makimoto G, Kudo K, Harada D, Ozaki Y, Nishio H, Tsuchihashi K, Miura Y, Endo M, Yano S, Maruyama D, Yoshinami T, Susumu N, Takekuma M, Motohashi T, Ito M, Baba E, Uchino K, Kimura T, Kamiyama Y, Nakao S, Tamura S, Nishimoto H, Kato Y, Sato A, Takano T, Kubo T. Ichihara E, et al. Among authors: nishio h. Int J Clin Oncol. 2024 Apr;29(4):355-362. doi: 10.1007/s10147-024-02469-4. Epub 2024 Feb 14. Int J Clin Oncol. 2024. PMID: 38353907
847 results